Abstract
Multiple sclerosis (MS) is a chronic autoimmune disease of the central nervous system that results in varying degrees of functional impairment. Conventional tools, such as the Expanded Disability Status Scale (EDSS), lack sensitivity to subtle changes in disease progression. Radiomics offers a quantitative imaging approach to address this limitation. This study used machine learning (ML) and radiomics features derived from T2-weighted Fluid-Attenuated Inversion Recovery (FLAIR) magnetic resonance images (MRI) to predict disability progression in people with MS (PwMS).
A retrospective analysis was performed on real-world data from 247 PwMS across two centers. Disability progression was defined using EDSS changes over two years. FLAIR MRIs were preprocessed using bias-field correction, intensity normalisation, and super-resolution reconstruction for low-resolution images. White matter lesions (WML) were segmented using the Lesion Segmentation Toolbox (LST), and MRI tissue segmentation was performed using sequence Adaptive Multimodal SEGmentation. Radiomics features from WML and normal-appearing white matter (NAWM) were extracted using PyRadiomics, harmonised with Longitudinal ComBat, and reduced via Spearman correlation and recursive feature elimination. Elastic Net, Balanced Random Forest (BRFC), and Light Gradient-Boosting Machine (LGBM) models were evaluated on validation data and subsequently tested on unseen data.
The LGBM model with harmonised radiomics and clinical features outperformed the clinical only model by achieving a test performance of PR AUC of 0.20 and a ROC AUC of 0.64. Key predictive features, among others, included GLCM maximum probability (WML), GLDM dependence non uniformity (NAWM). Short-term changes (longitudinal imaging approach) showed limited predictive power by achieving a PR AUC of 0.11 and a ROC AUC of 0.69.
These findings support the use of ML models trained on radiomics features integrated with clinical data for predicting disability progression in PwMS. Future studies should validate these findings in larger, balanced datasets and explore advanced approaches, such as deep learning and foundation models, to enhance predictive performance.
Competing Interest Statement
Hamza Khan: No conflict of interest or relevant disclosures to this study. Diana L. Giraldo: No conflict of interest or relevant disclosures to this study. Henry C Woodruff: Minority shares in the company Radiomics SA Lorin Werthen-Brabants: No conflict of interest or relevant disclosures to this study. Shruti Atul Mali: No conflict of interest or relevant disclosures to this study. Sina Amirrajab: No conflict of interest or relevant disclosures to this study. Edward De Brouwer: No conflict of interest or relevant disclosures to this study. Veronica Popescu: No conflict of interest or relevant disclosures to this study. Bart Van Wijmeersch: No conflict of interest or relevant disclosures to this study. Oliver Gerlach: No conflict of interest or relevant disclosures to this study. Jan Sijbers: No conflict of interest or relevant disclosures to this study. Liesbet M. Peeters: No conflict of interest or relevant disclosures to this study. Philippe Lambin: None related to the current manuscript; outside of current manuscript: grants/sponsored research agreements from Radiomics SA, Convert Pharmaceuticals SA and LivingMed Biotech srl. He received a presenter fee and/or reimbursement of travel costs/consultancy fee (in cash or in kind) from Astra Zeneca, BHV srl & Roche. PL has/had minority shares in the companies Radiomics SA, Convert pharmaceuticals SA, Comunicare SA, LivingMed Biotech srl and Bactam srl. PL is co-inventor of two issued patents with royalties on radiomics (PCT/NL2014/050248 and PCT/NL2014/050728), licensed to Radiomics SA; one issued patent on mtDNA (PCT/EP2014/059089), licensed to ptTheragnostic/DNAmito; one granted patent on LSRT (PCT/ P126537PC00, US patent No. 12,102,842), licensed to Varian; one issued patent on Radiomic signature of hypoxia (U.S. Patent 11,972,867), licensed to a commercial entity; one issued patent on Prodrugs (WO2019EP64112) without royalties; one non-issued, non-licensed patents on Deep Learning-Radiomics (N2024889) and three non-patented inventions (softwares) licensed to ptTheragnostic/DNAmito, Radiomics SA and Health Innovation Ventures). Philippe Lambin confirms that none of the above entities were involved in the preparation of this paper.
Funding Statement
This research received funding from the Flemish Government under the Onderzoeksprogramma Artificiele Intelligentie (AI) Vlaanderen program, Stichting Multiple Sclerosis Research (19-1040 MS), and the Bijzonder OnderzoeksFonds (BOF19DOCMA10). Authors acknowledge financial support from the European Union's Horizon research and innovation programme under grant agreements: ImmunoSABR n[deg] 733008, CHAIMELEON n[deg] 952172, EuCanImage n[deg] 952103, IMI-OPTIMA n[deg] 101034347, RADIOVAL (HORIZON-HLTH-2021-DISEASE-04-04) n[deg] 101057699, EUCAIM (DIGITAL-2022-CLOUD-AI-02) n[deg] 101100633, GLIOMATCH n[deg] 101136670, AIDAVA (HORIZON-HLTH-2021-TOOL-06) n[deg] 101057062, REALM (HORIZON-HLTH-2022-TOOL-11) n[deg] 101095435.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Ethics Committee of the University of Hasselt (CME2019/046) and the Medical Ethics Review Committee of Zuyderland and Zuyd University of Applied Sciences (METCZ20200167) provided ethical approval for this study. No consent to participate was required due to the retrospective nature of the research. All images were pseudonymized to ensure participant confidentiality.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.